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INTRODUCTION
Acute hepatitis A is one of the well known vaccine preven-
table diseases (1) and active hepatitis A virus (HAV) vacci-
nation is recommended in high risk populations (2). These
include the two major high risk groups for fatal fulminant
hepatic failure, those aged over 40 and patients with chron-
ic liver disease (CLD) (3-6). Mortality among patients with
HBsAg was found to be significantly higher than among
those without HBsAg in an outbreak of HAV infection in
Shanghai (7), and an analysis of HAV associated death in
the United States revealed higher case fatality rate among
chronic hepatitis B virus (HBV) carriers than among patients
without HBV (5). Moreover, patients with hepatitis C virus
(HCV) infection were reported to experience HAV associat-
ed fulminant hepatic failure more often than those without
CLD (8). Given the highly effective and safe vaccines now
available and a low rate of inherent immunity, the active im-
munization of CLD patients is emphasized in countries with
a low seroprevalence of anti-HAV (9). 
In Korea, where HBV is highly prevalent, age-specific
immunity against HAV in the adult population older than
30 yr was reported to be 100% in the early 1980s (10) and
more than 97% in 1999 (11). Therefore, the clinical signifi-
cance of acute HAV infection in adults was thought to be neg-
ligible, and it has been considered unnecessary, until recent-
ly, to test for the presence of anti-HAV antibody in adults,
even in high risk groups. However, as environmental condi-
tions have improved, the seroprevalence of anti-HAV has been
steadily decreasing in childhood (12), whereas the incidence
of overt acute hepatitis A has recently been increasing in adults
(13-15). These changes imply that more people reached adult-
hood without being exposed to HAV in childhood, and there-
fore, are at risk of developing symptomatic acute hepatitis
A. However, the consequences of these changes have not been
evaluated in CLD patients in Korea.
In this study, we restrospectively analyzed the changes of age
distributions of acute hepatitis A patients during the last de-
cade and prospectively investigated age-specific seroprevalences
of anti-HAV in CLD patients in a 3rd referral center in Korea.
MATERIALS AND METHODS
Retrospective analysis of the patients with acute hepatitis A
We retrospectively reviewed the medical records of patients
with acute hepatitis A, who were identified by the presence
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Emerging Need for Vaccination against Hepatitis A Virus in Patients
with Chronic Liver Disease in Korea
Vaccination against hepatitis A virus (HAV) is recommended for patients with chro-
nic liver disease (CLD), but this has been deemed unnecessary in Korea since the
immunity against HAV was almost universal in adults. However, this practice has
never been reevaluated with respect to the changing incidence of adult acute hep-
atitis A. We retrospectively reviewed the medical records of 278 patients with acute
hepatitis A diagnosed from January 1995 to November 2005 and prospectively tested
419 consecutive CLD patients from July to December 2005 for the presence of IgG
anti-HAV. The number of patients with acute hepatitis A has markedly increased
recently, and the proportion of adult patients older than 30 yr has been growing from
15.2% during 1995-1999, to 28.4% during 2000-2005 (p=0.019). Among 419 CLD
patients, the seroprevalences of IgG anti-HAV were 23.1% for those between 26
and 30 yr, 64% between 31 and 35 yr, and 85.0% between 36 and 40 yr. These
data demonstrate that immunity against HAV is no more universal in adult and sub-
stantial proportion of adult CLD patients are now at risk of HAV infection in Korea.
Therefore, further study on seeking proper strategy of active immunization against
HAV is warranted in these populations.
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of serum IgM antibody against HAV (Electrochemilumines-
cence, Roche Diagnostics Korea, Seoul) along with appro-
priate clinical manifestations from January 1995 to Novem-
ber 2005 at Ewha Womans University Mokdong Hospital.
Annual numbers of acute hepatitis A patients were plotted,
and the age distributions of patients were compared for the
periods 1995-1999 and 2000-2005.
Prospective analysis of the seroprevalences of IgG anti-
HAV in chronic liver disease patients
We prospectively tested the sera of consecutive chronic liver
disease patients who visited the outpatient department or
who were admitted to our hospital between July and Decem-
ber 2005, for the presence of IgG antibody against HAV using
a radioimmunoassay kit (Beijing North Institute of Biolog-
ical Technology, Beijing, China). Patients with chronic hep-
atitis B, chronic hepatitis C, alcoholic liver disease, liver cir-
rhosis, and hepatocellular carcinoma were included. Age-spe-
cific seroprevalences were analysed. 
Statistical analysis
Statistical analysis was performed using SPSS for Windows
(SPSS Inc, Chicago, IL, U.S.A.). Analysis was conducted using
the independent t test, chi-square test, and linear-by-linear
association, and p values of <0.05 were considered statisti-
cally significant.
RESULTS
Changes in the age distributions of the patients with acute
hepatitis A
A total of 278 patients with acute hepatitis A were select-
ed. The case number of acute hepatitis A was found to have
steadily increased during the last decade with an extraordi-
narily high eruption in 1998 (Fig. 1). The majority of patients
were in their twenties (21-30 yr, 49.6%) with a mean age of
24.9 yr, and 24.8% of the patients were adults older than 30
yr (Table 1). 
We arbitrarily divided the study period into before and after
the year 2000 to determine whether the numbers of adult
acute hepatitis A patients have increased recently. The age
distribution of the 79 patients in pre-2000 period (1995-
1999) was compared with that of the 199 patients in post-
2000 period. Mean age of the post-2000 patients was signif-
icantly higher than that of the pre-2000 patients (26 vs. 22
yr, p<0.001) and the proportion of patients older than 30 yr
was almost doubled between pre and post-2000 periods (15.2
% vs. 28.6%, p<0.001) (Table 1). Although the most preva-
lent age interval was unchanged (21-25 yr), the number of
patients older than 21 yr was markedly increased between the
two periods and that contributes to the most of recent increase
in the overall occurrence of acute hepatitis A (Fig. 2). 
*, p<0.001 between the two periods (by t-test, chi-square test).
Study period
1995-2005
1995-1999 2000-2005
Number of patients 278 79 199
Male:Female 133:145 41:38 92:107
Age (yr) distributions
-10 16 (5.8%) 9 (11.4%) 7 (3.5%)
11-15 21 (7.6%) 11 (13.9%) 10 (5.0%)
16-20 34 (12.2%) 18 (20.3%) 18 (9.0%)
21-25 76 (27.3%) 21 (26.6%) 55 (27.6%)
26-30 62 (22.3%) 10 (12.7%) 52 (26.1%)
31-35 49 (17.6%) 7 (8.7%) 42 (21.1%)
36-40 14 (5.0%) 5 (6.3%) 9 (4.5%)
41- 6 (2.2%) 0 (0%) 6 (3.0%)
Mean age (yr)* 24.9 22±82 6 ±8
≤30 yr 209 (75.2%) 67 (84.8%) 142 (71.4%)
>30 yr* 69 (24.8%) 12 (15.2%) 57 (28.6%)
Table 1. Age distributions of the acute hepatitis A patients dur-
ing 1995-1999 and 2000-2005
Fig. 2. Age distributions of acute hepatitis A patients during 1995-
1999 and 2000-2005, demonstrating recent increasing trends
among adult patients.
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Fig. 1. Annual case numbers of acute hepatitis A from 1995 to
2005 in our hospital. The number of acute hepatitis A patients have
markedly increased in recent years with an eruption in 1998. 
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Age-specific seroprevalences of anti-HAV in chronic liver
disease patients
Four hundred and nineteen chronic liver disease patients
were tested for serum IgG antibody against HAV from July
to December 2005. The mean age of patients was 52 yr and
67.5% were male. Most of the patients were >40 yr old (79%)
and 15% were in their thirties. HBV was associated in more
than 65% and alcohol in 17.7%, followed by HCV in 12.9%.
Other causes of chronic liver disease included primary biliary
cirrhosis (1 case), autoimmune hepatitis (10 cases), Budd-
Chiari syndrome (1 case), and cryptogenic liver cirrhosis (8
cases) (Table 2). 
The overall seroprevalence of anti-HAV in CLD patients
was 89.3% (374/419). As shown by Fig. 3, age-specific sero-
prevalences increased with age (p<0.001); 0% in patients
≤25 yr old, 23.1% in those between 26 and 30 yr, 64%
between 31 and 35 yr, 85.0% between 36 and 40 yr, 94%
between 41 and 45 yr, 100% between 46 and 55 yr, and 98%
in patients ≥56 yr old. According to these data, the seropre-
valence of anti-HAV in adults between 31 and 40 yr, which
had been reported to be more than 97% before 2000 (10, 11)
was substantially decreased, and about 25% of these patients
were at the risk of HAV infection. 
DISCUSSION
In Korea, acute symptomatic hepatitis A, which has been
steadily increased since the 1980s, has become one of the most
common causes of acute viral hepatitis (14). In the meantime,
childhood incidence has decreased (12) while its incidence
in adults has increased (13-15), as evidenced by the present
study (Fig. 1, 2). In 1998 an outbreak of acute hepatitis A
was recorded in several regions in Korea (11, 16). To charac-
terize chronological changes in the ages of affected patients,
we compared the age distributions of patients diagnosed in
the pre-2000 and post-2000 periods. The mean age of patients
was significantly higher in post-2000 and the relative propor-
tions of adult and elderly patients were significantly increased
(Table 1, Fig. 2). These results are in accordance with epide-
miologic changes in HAV infection reported in other Asian
populations (17), and reflect reduced immunity against HAV
in adult Koreans, (11, 12, 15) including those with chronic
liver disease for whom WHO recommends active vaccination.
As was anticipated, the seroprevalence of anti-HAV in mid-
dle aged adult CLD patients between the ages of 31 and 35
yr was only 64% in the present study, which was markedly
lower than the 100% that reported in 1982 (10), and even
15% of patients between the ages of 36 and 40 yr were found
to be at risk of HAV infection (Fig. 3). These data indicate
that a substantial proportion of CLD patients younger than
40 yr are now at the risk of acute HAV infection, more specif-
ically, 77% of patients aged 26 to 30 yr, 36% of those aged
31 to 35 yr, and 15% of those aged 36 to 40 yr. According-
ly, active immunization against HAV is demanded for these
populations. 
Patients older than 40 yr comprised 79% of 419 CLD
patients (Table 2), and more than 94% of these had already
acquired immunity against HAV, and thus, the majority of
CLD patients were free of HAV infection. However, if the
decreasing anti-HAV seroprevalence trend in adult contin-
ues, more CLD patients will be at risk of HAV infection in
the near future (18, 19). Cases of symptomatic HAV super-
infection in hepatitis virus carriers, which were very rare in
the 1980s, are being reported recently in Korea. In an anal-
ysis of clinical features of 177 acute hepatitis A patients, 12
patients with serologic evidences of hepatitis virus infection;
10 HBsAg positive and 2 anti-HCV positive, were identified
and mild clinical courses of these patients were described (15).
Others include; primary biliary cirrhosis, autoimmune hepatitis, Budd-
Chiari syndrome, and cryptogenic cirrhosis.
Characteristics Number (%)
Mean age (yr) 52
Male:Female 283 (67.5%):136 (32.5%)
Age (yr) interval 
-20 9 (2.1%)
21-25 5 (1.2%)
26-30 13 (3.1%)
31-35 23 (5.5%)
36-40 40 (9.5%)
41-45 54 (12.9%)
46-50 61 (14.6%)
51-55 54 (12.9%)
56- 160 (38.2%)
Etiology of chronic liver disease 
Hepatitis B virus (HBV) 270 (64.4%)
Hepatitis C virus (HCV) 54 (12.9%)
Alcohol 74  (17.7%)
HBV+HCV 3 (0.7%)
Others 20  (4.8%)
Table 2. Characteristics of the 419 patients with chronic liver di-
sease
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Fig. 3. Age-specific seroprevalences of anti-HAV antibody in pa-
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On the other hand, one case of fulminant acute hepatitis A
in an HBV carrier was reported in 2002, who suffered from
encephalopathy, azotemia and marked prolongation of pro-
thrombin time (20). In the present study, we identified two
cases of acute HAV superinfection in chronic viral hepatitis
patients, a 17-yr old female with chronic hepatitis C and a
35-yr old male with chronic hepatitis B. Both eventually
recovered from symptomatic acute hepatitis A with maxi-
mum serum aminotransferase levels of 937 and 2,976 IU/mL,
respectively. The 35-yr old male patient experienced more
severe hepatitis with a mild prolongation of prothrombin
time (70%, Internatinal Normalized Ratio 1.21). 
In terms of active immunization modalities, different im-
munization strategies can be implemented, depending on
the underlying anti-HAV seroprevalence rates (21, 22); when
anti-HAV seroprevalence rate is high, selective vaccination
according to anti-HAV serostatus is more cost-effective than
universal vaccination. In an analysis of the cost-effectiveness
of different vaccination strategies in CLD patients, Saab et al.
found that screening for anti-HAV became less costly than
vaccination without checking HAV serology when anti-HAV
prevalence exceeded 35% and the cost of serologic testing
was less than US$25 (23). Anti-HAV seroprevalence rates
by age, as determined by the present study, may provide
principal data for adjusting adequate vaccination strategy in
CLD patients. For example, instituting selective vaccination
for 31-40 yr old CLD patients (anti-HAV rate of 64-85%)
and universal vaccination for patients younger than 31 yr (anti-
HAV rate of 0-34%).
In addition to seroprevalence data, the cost of serologic test-
ing, the cost of vaccination, patient compliance, and the like-
lihood of the occurrence of a clinically significant fatal HAV
superinfection should also be determined to facilitate the iden-
tification of the most efficient vaccination strategy. In young
or childhood CLD patients, the serum anti-HAV rate is very
low and the risk of infection is high, but the symptomatic
infection rate and the risk of severe hepatic failure are mini-
mal and natural life long immunity is frequently attained
after a mild or asymptomatic infection. Therefore, the selec-
tive HAV vaccination of middle aged adult CLD patients
appears more urgent than the universal vaccination for younger
CLD patients (24). Further nationwide large scale studies,
including the active evaluation of the clinical significance of
acute HAV infection and cost-benefit analyses of different
vaccination strategies in different age groups of CLD patients
will provide firmer data for designing an optimal vaccination
strategy.
This single center study demonstrates that adult patients
with acute hepatitis A are more frequently encountered recen-
tly and that a substantial proportion of adult patients with
CLD are now susceptible to HAV infection. Although the
occurrence of acute hepatitis A was analyzed retrospectively
and this study was conducted in a third referral center hos-
pital, the observed increase of acute hepatitis A patients in
the adult population is concordant with previously reported
data (11, 13, 15) and, to our knowledge, no prospective analy-
sis of the age-specific seroprevalences of anti-HAV antibody
in CLD patients has been conducted before in this HBV en-
demic area. The results of this study provide an evidence of
emerging needs for HAV vaccination in adult CLD patients
in Korea and for large scale investigations to find out proper
vaccination strategy in these patients.
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